Interim analysis: CheckMate-274 trial of nivolumab in patients with high-risk, muscle-invasive urothelial carcinoma meets primary endpoints

CheckMate-274 study in participants with muscle-invasive urothelial cancer at a high risk of recurrence after radical surgery met its primary endpoints of improving disease-free survival versus placebo in all randomised patients and in patients whose tumor cells express PD-L1 ≥1%

Source:

Biospace Inc.